Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.

Ray N, Harrison JE, Blackburn LA, Martin JN, Deeks SG, Doms RW.

J Virol. 2007 Apr;81(7):3240-50. Epub 2007 Jan 24.

2.
3.

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.

Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labernardière JL, Pacanowski J, Meynard JL, Hance AJ, Clavel F, Mammano F.

J Virol. 2006 Sep;80(17):8807-19.

4.
5.
6.

Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.

Baatz F, Nijhuis M, Lemaire M, Riedijk M, Wensing AM, Servais JY, van Ham PM, Hoepelman AI, Koopmans PP, Sprenger HG, Devaux C, Schmit JC, Perez Bercoff D.

PLoS One. 2011;6(7):e21535. doi: 10.1371/journal.pone.0021535. Epub 2011 Jul 8.

7.

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC.

Antimicrob Agents Chemother. 2002 Jun;46(6):1896-905.

8.

Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Reeves JD, Gallo SA, Ahmad N, Miamidian JL, Harvey PE, Sharron M, Pohlmann S, Sfakianos JN, Derdeyn CA, Blumenthal R, Hunter E, Doms RW.

Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54. Epub 2002 Nov 20.

9.

Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo.

Trabaud MA, Cotte L, Labernardière JL, Lebel-Binay S, Icard V, Tardy JC, Trepo C, Andre P.

J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):134-44.

PMID:
17621239
10.

Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.

Poveda E, Rodés B, Labernardière JL, Benito JM, Toro C, González-Lahoz J, Faudon JL, Clavel F, Schapiro J, Soriano V.

J Med Virol. 2004 Sep;74(1):21-8.

PMID:
15258964
11.

Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.

Charpentier C, Jenabian MA, Piketty C, Karmochkine M, Tisserand P, Laureillard D, Bélec L, Si-Mohamed A, Weiss L.

Scand J Infect Dis. 2011 May;43(5):373-9. doi: 10.3109/00365548.2011.552520. Epub 2011 Feb 22.

PMID:
21341978
12.

Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR.

J Virol. 2004 May;78(9):4628-37.

13.

Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.

Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfield-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML.

J Virol. 2005 Oct;79(19):12447-54.

14.

Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy.

Poveda E, Rodés B, Lebel-Binay S, Faudon JL, Jimenez V, Soriano V.

J Clin Virol. 2005 Dec;34(4):295-301.

PMID:
16286053
15.

The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype.

Cunyat F, Marfil S, García E, Svicher V, Pérez-Alvárez N, Curriu M, Perno CF, Clotet B, Blanco J, Cabrera C.

Retrovirology. 2012 Feb 14;9:15. doi: 10.1186/1742-4690-9-15.

16.

Genotypic analysis of the gp41 HR1 region from HIV-1 isolates from enfuvirtide-treated and untreated patients.

Pessoa LS, Valadão AL, Abreu CM, Calazans AR, Martins AN, Azevedo SS, Couto-Fernandez JC, Azevedo MC, Tanuri A.

J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 3:S197-201. doi: 10.1097/QAI.0b013e31821e9d29.

PMID:
21857318
17.

High prevalence of primary Enfuvirtide (ENF) resistance-associated mutations in HIV-1-infected patients in Hong Kong.

Leung PH, Chen JH, Wong KH, Chan KC, Lam HY, Cheng VC, Yuen KY, Yam WC.

J Clin Virol. 2010 Mar;47(3):273-5. doi: 10.1016/j.jcv.2010.01.002. Epub 2010 Jan 29.

PMID:
20116329
18.

Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.

Svicher V, Alteri C, D'Arrigo R, Laganà A, Trignetti M, Lo Caputo S, Callegaro AP, Maggiolo F, Mazzotta F, Ferro A, Dimonte S, Aquaro S, di Perri G, Bonora S, Tommasi C, Trotta MP, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F.

Antimicrob Agents Chemother. 2009 Jul;53(7):2816-23. doi: 10.1128/AAC.01067-08. Epub 2009 Jan 5.

19.

Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

Xu L, Pozniak A, Wildfire A, Stanfield-Oakley SA, Mosier SM, Ratcliffe D, Workman J, Joall A, Myers R, Smit E, Cane PA, Greenberg ML, Pillay D.

Antimicrob Agents Chemother. 2005 Mar;49(3):1113-9.

20.

Supplemental Content

Support Center